May 2026 Data (June Edition)

Section A: The Themes Hidden in May's Lobbying Data

Critical Medicines Act Targets Supply Chain Weaknesses

A surge in lobbying by basic pharmaceutical manufacturers such as Bioiberica SAU and MEDICINES FOR EUROPE in May 2026 coincides with the EU's political agreement on the Critical Medicines Act, which aims to remedy medicine shortages and API supply vulnerabilities. The Act introduces procurement criteria favoring EU-based production and more robust resilience requirements, reflecting structural concerns raised in recent lobbying exchanges with the Direct. Gen. Health and Animal Welfare. This mirrors observed stakeholder pressure, especially around heparin API supply and critical medicine topics raised in meetings with Bioiberica SAU.

📎 EU advances Critical Medicines Act for securing EU API supply · Critical Medicines Act: end of critical medicine shortages once and for all · EU Critical Medicines Act - political agreement reached: what life sciences companies need to know

Pharma Package Reform Fuels Intense Industry Dialogue

Lobbying from major pharmaceutical companies such as Bayer AG, GSK, and Eli Lilly and Company, as well as sector groups like the European Federation of Pharmaceutical Industries and Associations, peaked during final negotiations on the EU 'pharma package' this spring. The reforms overhaul access, exclusivity, supply mandates, and incentives for innovation—particularly for antibiotics—and have triggered industry efforts to shape implementation and address new regulatory duties, with frequent engagement involving Comm Varhelyi (Health and Animal Welfare). These developments coincide with a measurable spike in meetings focusing on challenges and priorities for health and life sciences.

📎 Reform of EU pharmaceutical legislation

Healthcare Lobbying Responds to European Biotech Act Negotiations

Intensive lobbying from biotechnology firms, including direct advocacy on the 'Biotech Act,' aligns with ongoing negotiations in Parliament and Council to streamline regulation and boost sector capacity. The Act addresses gaps in manufacturing, clinical trial acceleration, and biosecurity previously flagged in stakeholder meetings. This pattern of engagement comes as the Commission seeks to harmonize regulatory sandboxes and support innovative therapies.

📎 European Biotech Act

Cancer Mission Calls Reflect Active Research Lobbying

The opening of the 2026 'Mission Cancer' funding calls closely coincides with lobbying activity from research organizations and new sector entrants such as the European Cancer Organisation, Bayer AG, and GSK, especially on oncology innovation topics. Engagements focused on cancer research priorities—including digital tools and patient-centric care—mirrored the Commission's objectives for the initiative, with notable meetings involving Comm Varhelyi and Comm Zaharieva. Advocacy for these priorities was evident in meetings with officials overseeing startups and research portfolios.

📎 Cancer Mission calls 2026 - European Health and Digital Executive ... · EU launches 2026 Horizon Europe call to advance cancer research

Commissioner Varhelyi Meetings Mark Sector Engagement Peak

A marked increase in meetings between Commissioner Varhelyi (Health and Animal Welfare) and leading pharmaceutical companies—including Eli Lilly and Company, Bayer AG, and A. Menarini Industrie Farmaceutiche Riunite—signals alignment with freshly negotiated EU healthcare policies. The timing suggests organizations such as Novartis International AG are seeking direct input on how new legislation like the Critical Medicines Act and Pharma Package might impact their operations and supply strategies.

📎 “Under enormous pressure”: EU Commissioner Várhelyi warns over future ...

Section B: Lobbying Activity by Industry

This section compares, by industry, the lobbying activity with the European Commission last month to its historical average.

Industry Lobbying Activity, May 2026

In May 2026, 5 industries from this sector were active in lobbying meetings with the European Commission, led by Pharmaceutical preparations.

Industries running notably above their historical average this month include Basic pharmaceutical products.

On the quieter side, Pharmaceutical preparations, Other Social Work w/o Accommodation, Other Human Health, and Medical and Dental Instruments saw notably less lobbying activity than their historical average.

Section C: Lobbying by Industry for the Past Year

To contextualize Section B, this chart shows the residual trajectory of the same top industries from Section B over the past 12 months — the deviation from what would be expected after accounting for seasonal patterns and the overall trend. Persistent above-zero values indicate sustained over-activity; persistent below-zero values indicate sustained quiet periods.

Industry Lobbying Residuals, May 2026

This chart shows the 5 industries in this sector with the largest deviations from expected lobbying activity in May 2026. Positive values run above their seasonal trend, negative values below.

Other Social Work w/o Accommodation, Pharmaceutical preparations, Other Human Health, Medical and Dental Instruments, and Basic pharmaceutical products saw lobbying notably below expected levels this month.

Section D: Lobbying Activity by Organization

In this section, we see the organizations with the most unusual lobbying behavior last month, defined by either unusually high or unusually low lobbying activity.

Organization Lobbying Activity, May 2026

In May 2026, 40 organizations from this sector took part in 27 lobbying meetings with the European Commission.

The organizations with the most notable increases in lobbying activity this month include Eli Lilly and Company, A. Menarini Industrie Farmaceutiche Riunite s.r.l., Chemicals, Health and Environment Monitoring Trust, and Bristol-Myers Squibb Company.

On the quieter side, MedTech Europe, Gates Foundation, International Federation of Red Cross and Red Crescent Societies, European Federation of Pharmaceutical Industries and Associations, and EuropaBio saw notably less lobbying activity than usual.

New to the sector's lobbying records this month: American Near East Refugee Aid, Vertanical GmbH, and Boston Scientific International SA.

Section E: Lobbying of Government Institutions in the Past Month

Every lobbying meeting takes place with one of two types of European Commission body: a Commissioner's cabinet (political staff) or a Directorate-General (the civil service). This section shows the organisation-to-institution pairings with the most unusual lobbying activity last month, defined by the largest absolute difference between this month's meeting count and the pair's 12-month rolling average.

Lobbying of Commission Institutions, May 2026 vs 12-Month Avg

In May 2026, 40 organisations from this sector met with 14 Commission bodies across 27 meetings — split across 9 Commissioner cabinets and 5 Directorates-General.

Notable increases in lobbying activity this month include A. Menarini Industrie Farmaceutiche Riunite s.r.l. with Comm Varhelyi (Health and Animal Welfare), Eli Lilly and Company with Comm Varhelyi (Health and Animal Welfare), and Bayer AG with Comm Varhelyi (Health and Animal Welfare).

Section F: Organization Lobbying by Subject in the Past Month

This section shows the organisation-to-subject pairings with the most unusual lobbying activity last month. Subjects are classified from each meeting's title text into one of 19 EU policy areas. A meeting covering multiple topics counts toward each of them.

Lobbying by Subject, May 2026 vs 12-Month Avg

In May 2026, 39 organisations from this sector lobbied on 7 policy topics across 27 meetings. Meetings may touch multiple topics, so subject totals can exceed total meetings.

Topics with notably elevated lobbying activity this month include A. Menarini Industrie Farmaceutiche Riunite s.r.l. on Healthcare, Eli Lilly and Company on Healthcare, and Chemicals, Health and Environment Monitoring Trust on Environment.

On the quieter side, MedTech Europe on Healthcare, European Federation of Pharmaceutical Industries and Associations on Healthcare, and Merck Sharp & Dohme Europe Belgium SRL on Healthcare saw notably less lobbying activity than their historical average.

Section G: Most-Lobbied Officials

This section lists the most-frequent lobbying touchpoints between this sector's organisations and individual European Commission officials last month, compared to each pairing's average over the past year.

Most-Lobbied Officials, May 2026

In May 2026, 25 European Commission officials took part in 27 meetings with this sector's lobbyists.

The most-frequent meetings this month were Eli Lilly and Company and Oliver Varhelyi + 1 other at Comm Varhelyi (Health and Animal Welfare), Bayer AG and Oliver Varhelyi at Comm Varhelyi (Health and Animal Welfare), A. Menarini Industrie Farmaceutiche Riunite s.r.l. and Oliver Varhelyi + 1 other at Comm Varhelyi (Health and Animal Welfare), European Cancer Organisation and Ekaterina Zaharieva + 1 other at Comm Zaharieva (Startups and Research), and Bristol-Myers Squibb Company and Oliver Varhelyi + 1 other at Comm Varhelyi (Health and Animal Welfare).

Most activity came from Cabinet members (45 meetings), followed by Commissioner (21) and Head of Unit (5).